| EJNMMI Research | |
| Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation | |
| Original Research | |
| Martin Gotthardt1  Maarten de Bakker1  James Nagarajah1  Bastiaan M. Privé1  Frank de Lange1  Steffie M. B. Peters1  Maaike C. T. Mink2  Mark W. Konijnenberg3  Niven Mehra4  J. Alfred Witjes5  Constantijn H. J. Muselaers5  | |
| [1] Department of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands;Department of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands;Department of Physics and Astronomy, Radboud University, Nijmegen, The Netherlands;Department of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands;Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands;Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands;Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands; | |
| 关键词: [Lu]Lu-PSMA; Dosimetry; Radionuclide therapy; Prostate cancer; mHSPC; | |
| DOI : 10.1186/s13550-023-00952-z | |
| received in 2022-07-25, accepted in 2023-01-11, 发布年份 2023 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundDosimetry in [177Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol to determine the absorbed dose in organs and tumor lesions after [177Lu]Lu-PSMA-617 therapy, by reducing the imaging time points and utilizing population-based kinetics with a single scan, with evaluation of its influence on the uncertainty in absorbed dose.MethodsTen patients with metastatic hormone-sensitive prostate cancer received two cycles of [177Lu]Lu-PSMA-617. Post-treatment imaging was performed at 1 h, 24 h, 48 h, 72 h and 168 h, consisting of three-bed positions SPECT/CT and a whole-body planar scan. Five-time point SPECT dosimetry was performed for lesions and organs with physiological uptake (kidneys, liver and salivary glands) and used as the reference standard. Absorbed dose values for various simplified protocols were compared to the reference standard.ResultsAccurate lesion dosimetry is possible using one-time point SPECT imaging at 168 h, with an increase in uncertainty (20% vs. 14% for the reference standard). By including a second time point, uncertainty was comparable to the reference standard (13%). Organ dosimetry can be performed using a single SPECT at 24 h or 48 h. Dosimetry based on planar scans did not provide accurate dose estimations.ConclusionAccurate lesion dosimetry in [177Lu]Lu-PSMA therapy can be performed using a one- or two-time point protocol, making dosimetry assessments more suitable for routine clinical implementation, although dosimetry based om multiple time points is more accurate.Clinical trial registration This study was approved by the Medical Review Ethics Committee Region Arnhem-Nijmegen on January 23, 2018 and was registered on clinicaltrials.gov (NCT03828838).
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202305113998087ZK.pdf | 1217KB | ||
| 41116_2022_35_Article_IEq11.gif | 1KB | Image | |
| Fig. 4 | 521KB | Image | |
| Fig. 6 | 171KB | Image | |
| 40249_2022_1049_Article_IEq39.gif | 1KB | Image | |
| 40249_2022_1049_Article_IEq44.gif | 1KB | Image |
【 图 表 】
40249_2022_1049_Article_IEq44.gif
40249_2022_1049_Article_IEq39.gif
Fig. 6
Fig. 4
41116_2022_35_Article_IEq11.gif
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
PDF